Injectable Drug Delivery Market

Market Overview

The global injectable drug delivery market size was valued at USD 692.1 billion in 2023 and is projected to reach USD 1,982.0 billion by 2032, registering a CAGR of 12.4% during the forecast period (2024-2032). One of the key drivers of this market's overall growth is the increasing prevalence of chronic diseases worldwide. 

Injectable drug delivery is administering drugs directly into the body's tissues. This method of drug delivery bypasses the gastrointestinal tract, allowing drugs to be quickly absorbed and distributed into the circulation. Injectable medications can be administered by a variety of methods, including intravenous (IV), intramuscular (IM), subcutaneous (SC), intradermal (ID), and intrathecal injections, depending on the drug's characteristics, therapeutic indication, and desired pharmacokinetic profile.

The market for injectable medications has increased significantly in recent years due to their numerous benefits, including safety, efficacy, and improved stability. Injectable drug delivery technology has advanced considerably during the previous few years. One of the most recent trends in the worldwide injectable medication delivery technology market has been the rise in self-administration. According to our injectable drug delivery technology market insights, leading manufacturers and research institutes are increasing their research and development efforts to create innovative products, boosting demand.

Highlights

• Conventional Injectable holds the significant market share by device type.
• Injectable Sterile Products influenced the market by product type.
• Hospitals are the major end-users of the market.

Market Dynamics

Global Injectable Drug Delivery Market Drivers

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular problems, and autoimmune diseases increases the demand for injectable medication delivery systems. These disorders frequently necessitate long-term pharmaceutical care, and injectable formulations provide advantages in terms of accurate dosing, increased bioavailability, and greater patient compliance. Diabetes is a chronic metabolic condition marked by elevated blood sugar levels. Injectable insulin therapy is critical to diabetes management, especially for patients with type 1 diabetes who require exogenous insulin to control blood glucose levels.

According to The Lancet, diabetes affects more than half a billion people worldwide, and this figure is expected to more than quadruple to 1.3 billion in the next 30 years. Diabetes is among the top ten leading causes of death and disability. It can harm the eyes, kidneys, nerves, and heart and is connected to some types of cancer. The rising global prevalence of diabetes, fueled by factors such as sedentary lifestyles, poor diets, and aging populations, adds to the demand for injectable insulin formulations and delivery systems.

Additionally, cancer is a global public health concern, accounting for 9.6 to 10 million fatalities worldwide in 2023, or approximately 26,300 deaths each day. People aged 69 and younger account for 57% of all new cancer cases and 47% of cancer deaths. As cancer rates continue to climb due to factors such as aging populations, environmental exposures, and lifestyle choices, the demand for injectable cancer medicines is predicted to rise.

Furthermore, by 2023, more than 620 million individuals, or around 60 million annually, will have heart and circulation illnesses. Cardiovascular diseases (CVDs) are the leading cause of death worldwide, accounting for 17.9 million deaths annually. In 2021, CVD caused 20.5 million deaths, accounting for over a third of all fatalities worldwide. With risk factors such as tobacco use, poor diets, physical inactivity, and problematic alcohol use all contributing to the cardiovascular disease epidemic, the need for injectable cardiovascular medicines is expected to increase to satisfy the healthcare needs of impacted communities.

Global Injectable Drug Delivery Market Restraints

Safety Concerns and Side-Effects

Adverse effects associated with injectable drug administration include injection site responses, allergic reactions, infections, and tissue damage. Concerns regarding the safety profile of injectable drugs may dissuade patients and healthcare providers from choosing injectable therapy, especially when other methods of administration are available. Manufacturers must meet severe regulatory standards to assure the safety and efficacy of injectable drug delivery systems, which can raise development costs and regulatory barriers.

According to the 2023 practice parameter update, certain patients may have adverse responses to injectable medications. Type I reactions include anaphylaxis, urticaria, and angioedema. Anaphylaxis, often known as "anaphylactic shock," is a severe type of reaction that can be fatal in rare situations. Most medication allergies involve mild skin rashes and hives, which might appear immediately or several hours later.

Moreover, improper injection procedures, inadequate aseptic measures, and contaminated equipment can cause injection site infections or systemic infections such as cellulitis, abscess formation, and bloodstream infections. Healthcare-associated infections linked to injectable drug administration endanger patient safety and may necessitate antimicrobial therapy and supportive care. In 2023, the FDA reported 98 newly identified safety signals (NISS), one of which was associated with an error in the delivery of naloxone hydrochloride. The issue occurred when someone attempted to inject a syringe that did not have a needle. 

Global Injectable Drug Delivery Market Opportunity

Rising Demand for Targeted Therapies

The rising frequency of complicated diseases such as cancer, autoimmune disorders, and infectious diseases increases the demand for tailored medicines administered using injectable drug delivery systems. Targeted medicines have the potential to improve efficacy, reduce adverse effects, and provide personalized treatment approaches based on unique patient features, genetic profiles, and disease subtypes. Injectable formulations allow for precision dosing, controlled release, and targeted distribution of drugs to specific tissues, organs, or cells, resulting in optimal therapeutic outcomes.

Furthermore, cancer-targeted medicines, such as monoclonal antibodies, tyrosine kinase inhibitors, and immune checkpoint inhibitors, have transformed treatment by targeting cancer cells or molecular pathways while sparing healthy cells. Injectable versions of these targeted medicines provide precision dosage and distribution to tumor locations, maximizing therapeutic efficacy while minimizing systemic toxicity. 

In contrast, injectable biologic medicines have revolutionized the treatment of autoimmune illnesses such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease by regulating the immune response and lowering inflammation. Adalimumab (Humira), etanercept (Enbrel), and ustekinumab (Stelara) are drugs that are delivered subcutaneously or intravenously to target specific cytokines or immune cells implicated in the pathogenesis of autoimmune disorders, giving symptom relief and improving disease outcomes.

Regional Analysis

The global injectable drug delivery market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global injectable drug delivery market shareholder and is estimated to grow at a CAGR of 11.8% over the forecast period. The increased adoption of novel injectable drug delivery systems by diabetes, cancer, and other autoimmune condition patients in North America is a key factor driving regional market expansion. Furthermore, these injectables' convenience and therapeutic benefits drive up demand, allowing North America to dominate the global industry. The increased prevalence of diabetes and cancer patients in the United States also adds to the market growth in North America. According to the American Diabetes Association (ADA), 11.6% of Americans had diabetes in 2023, with 1.2 million diagnosed each year. 

Additionally, the large population suffering from various chronic conditions is fueling the country's demand for injectable drug delivery products. According to the Centers for Condition Control and Prevention (CDC), around six people out of every ten are currently living with a chronic condition such as cancer, heart disease, or diabetes in the United States. These considerations lead to an expansion of the injectable medicine delivery business in this country. Furthermore, critical regional manufacturers are projected to help develop innovative injectable medication delivery devices, such as smart wearables and auto-injectors, which are predicted to boost the market during the forecast period. 

Asia-Pacific is anticipated to exhibit a CAGR of 12.0% over the forecast period due to increased awareness of these delivery systems, a larger patient pool, and a change from conventional drug delivery injection to ready-to-use injectables. By the end of 2022, China had 280.04 million individuals aged 60 and up, accounting for 19.8% of the national population (with 209.78 million aged 65 and up, representing 14.9% of the national population) (National Bureau of Statistics of China, 2023). The growing aging population drives up demand for self-injectors. This would eventually benefit the expansion of the Chinese injectable medicine delivery market.

Europe holds a significant market share. Increased research and development in this country has resulted in dominance in the European insulin pen market. Two German firms, Emperra GmbH E-Health Technologies and Pendiq Intelligent Diabetes Care, created and sold ESYSTA and Pendiq insulin pens, respectively. All of this helps to increase the market in Germany.

Furthermore, the United Kingdom is currently struggling with the issue of increased obesity rates in the general population. According to a January 2023 research briefing, 26% of adults in England are obese, with 38% overweight. Obesity prevalence has declined year after year, from 23.4% in 2022 to 22.7% in 2023, but it remains higher than before the epidemic. For example, the UK's Medicines and Healthcare Products Regulatory Agency has approved Eli Lilly's injectable diabetic medicine for weight loss treatment.

Latin America, the Middle East and Africa had less market potential in 2023. Brazil has seen an upsurge in sexually transmitted diseases (STDs) in recent years, with the rate expected to reach 31,745.5 cases per 100,000 people by 2023, ranking sixth in the world. This represents one out of every three people. In the first half of 2023, there were 89,386 STI consultations, a 12% increase over the first half of 2022. This has prompted drug delivery businesses to create injectable pharmaceuticals and devices to fight the rising health crisis. 

Moreover, many corporations have already requested approval from Brazil's regulatory organizations. For example, in June 2023, Anvisa, Brazil's federal health agency, approved injectable cabotegravir, a pre-exposure prophylaxis (PrEP) medicine for HIV.

Segmental Analysis

The global injectable drug delivery market is segmented based on device type, product type, and end-user.

The market is further segmented by device type into Conventional Injectable, Pre-filled syringes, Auto-injectors, Pen Injectors, and Wearable.

The conventional injectable category led the global market in 2023, owing to higher sales of traditional syringes due to increased hospitalization, rising prevalence of infectious diseases requiring hospital treatment, and an increasing number of operations worldwide. Conventional injectable devices consist of vials, ampoules, and individual syringes and needles, which healthcare practitioners must assemble and administer manually. Furthermore, these devices are commonly used in clinical settings to administer injectable drugs, allowing for more dosage flexibility and drug compatibility. However, they may provide precision, safety, and convenience difficulties compared to more advanced delivery systems. The increasing number of immunization programs around the world will help to drive the expansion of this category.

Pre-filled syringes are pre-filled by the manufacturer with a single dose of medication and are ready to use immediately. They provide benefits in ease, accuracy, reduced risk of dosing errors, and improved safety and sterility compared to traditional injectable devices. Pre-filled syringes are extensively used for patients to self-administer injectable drugs at home or in outpatient settings, especially for chronic conditions that require frequent doses.

Based on product type, the market is fragmented into Freeze-dried, Injectable Sterile Products.

The injectable sterile products category dominates due to its quality assurance and storability properties. Injectable sterile goods include a wide range of pharmaceutical formulations designed for parenteral delivery through injection routes such as intramuscular (IM), subcutaneous (SC), and intravenous (IV). These goods are made under stringent aseptic conditions to assure patient sterility and safety. Injectable sterile products can be packaged as liquid solutions, suspensions, or emulsions in vials, ampoules, pre-filled syringes, or other delivery devices. Surgeons often prefer sterile items in hospitals and clinics while performing surgeries or treating complex disorders. Injectable sterile are pathogen-free, representing a lesser risk of infection, which aids in the market expansion of this category.

The freeze-dried products segment is expected to increase quickly over the projection period. Freeze-dried or lyophilized products are pharmaceutical formulations that go through the freeze-drying (lyophilization) process to eliminate water and provide long-term stability. This method involves freezing and vacuuming the product to remove ice crystals while avoiding structural damage to the active pharmaceutical ingredient (API) or excipients. The new product type has been widely selected to increase the drug's bioavailability and patient compliance. Demand for freeze-dried products is expected to rise due to their ability to supply stabilized formulations.

The market is further bifurcated by End-users into hospitals, home care settings, and clinics.

Hospitals are expected to dominate the injectable medicine delivery market during the projected period. Hospitals are a significant end-user category for injectable drug delivery solutions, accounting for a sizable share of market demand. Hospitals are the principal providers of acute and specialized healthcare services, such as inpatient care, emergency treatment, surgical procedures, and diagnostic investigations. Injectable drugs are routinely used in hospital departments such as emergency rooms, operating rooms, intensive care units (ICUs), and outpatient clinics to treat various medical diseases and patient demographics. This dominance stems from an increase in hospital stays for people suffering from chronic or acute wounds. 

The clinics category is predicted to rise at a substantial CAGR over the forecast period, owing to a growth in stand-alone clinics in both developed and emerging markets. Clinics, including ambulatory care centers, outpatient clinics, specialty clinics, and community health centers, are essential in providing primary and specialist healthcare services to patients outside hospitals. Clinics offer diagnostic, therapeutic, preventative, and rehabilitative treatments to a broad patient population from numerous medical professions and subspecialties. During the exceptional COVID-19 outbreak, home healthcare is one of the best services available at your door.

Recent Developments

• March 2024- BD expanded domestic production to meet U.S. healthcare syringe needs.
• January 2024- SHL Medical strengthened its vertical capabilities by acquiring Superior Tooling Inc., a US manufacturer.
• March 2024- SCHOTT Pharma expanded in the United States with a new pre-fillable syringe manufacturing facility in Wilson, North Carolina.